CURRICULUM VITAE

ALEX WAIMING TONG, Ph.D.

ADDRESS

Cancer Immunology Research Laboratory
Baylor Sammons Cancer Center
Baylor University Medical Center
3500 Gaston Avenue
Dallas, TX 75246
(214) 820-4123 (ph)
(214) 820-2780 (fax)
(972) 900-3328 (blackberry)
alext@baylorhealth.edu

CURRENT APPOINTMENTS

Associate Director, Immunology Laboratory,
Baylor University Medical Center (BUMC),
Dallas, TX 75246 (since 1986).

Director of Preclinical Operations
Mary C. Crowley Medical Center
Dallas, TX 75246 (since 2004)

Professor, Institute of Biomedical Studies,
Baylor University, Waco, TX (since 2001).

Adjunct Associate Professor, Immunology Graduate Studies Program
Univ. Texas Southwestern Medical Center, Dallas (since 1986).

ACADEMIC DEGREES

Ph.D. (1980; Microbiology & Immunology)
Oregon Health Sciences University, Portland, OR
B.A. (1973; Biology)
University of Oregon, Eugene, OR

PROFESSIONAL MEMBERSHIPS

American Association of Immunologists
American Association for Cancer Research
American Society of Hematology
American Society for Gene Therapy.

HONORS AND AWARDS

Ad Hoc Reviewer for Blood, Cancer Detection and Prevention, Cancer Research, Clin. Cancer Research, Expert Opinion on Emerging Drugs, Gene Therapy, Human Gene Therapy, J Clin Oncology, Proc. Natl. Acad. Sci, USA, Cancer Research UK.

Principal Investigator, 2006-2007;
PHS R41 CA108039-01
Principal Investigator, 2001-2002
Dept Defense Grant DAMD17-01-1-0479.
Principal Investigator, 1994-1996
PHS Grant IR21CA63522-01
National Cancer Institute, NIH, Bethesda, MD 20892
Principal Investigator, 2001-2003

Summerfield Robertts Grant on myeloma gene transfer.
Principal Investigator, 2004-2007.
Leukemia Association of North Central Texas.
Principal Investigator, 2000-2004
Introgen Pharmaceutical Research Grant on mda-7 (IL-24).
Co-Principal Investigator, 2001-2002.
Onyx Pharmaceutical Research Grant on cancer patient immune response to oncolytic virus (ONYX 015) infusion.
Tartar Research Fellowship, 1981-1983
Medical Research Foundation of Oregon, Portland, OR

POST-GRADUATE MENTORSHIP

Yu-An Zhang (PhD, 1997)	Growth inhibition of human non-small cell lung cancer cells by anti-K- ras ribozymes.
Bryan K. Seamour (PhD, 1998)	Effect of autocritic interleukin-6 on human myeloma cells.
Craig C. Chappel (MS, 1999)	Representational display analysis of the growth inhibitory outcome of farnesyl transferase inhibitors on human non-small cell lung cancer.
Maria Papayotic (PhD, 2000)	Growth regulation of human breast cancers by CD40 ligand.
Caroline Hunter (MS, 2001)	Cytokine response of tumor patients receiving intravenous infusion of a replication-selective adenoviral vector.
Yan Zheng (MS, 2001)	Conditional expression of CD40L (CD154) under the control of a tetracycline-inducible promoter in human breast cancer.
Erica Gomes (PhD, 2006)	Anti-tumor properties of CD40 ligand when delivered as a transgene by the conditional replicative, oncolytic adenovirus AdEH to breast cancer cells.

PAST PROFESSIONAL & RESEARCH EXPERIENCE

2001-2004	Scientific Director, Molecular and Cell Processing Center US Oncology Research, Dallas, TX
1997-2001	Associate Professor**,** Institute of Biomedical Studies, Baylor University.
1988-1997	Assistant Professor, Institute of Biomedical Studies, Baylor University.
1982-86	Research Associate in Immunology, Charles Sammons Cancer Center, Baylor University Medical Center.
1980-1982	Postdoctoral Fellow, Surgical Research Laboratory, Portland VA Medical Center, OR. The study of transfer factor-related immuno-therap**y** with Dr. Denis R. Burger
1977-78	Teaching Assistant, School of Medicine, Oregon Health Sciences University.
1975-80	Research Assistant & Graduate Student, Dept. Microbiology & Immunology, Oregon Health Sciences University (1975-80); Thesis on tumor and autoimmune antigen recognition with Dr. Arthur Vandenbark
1972-73	Undergraduate Teaching Assistant, Biology Department, University of Oregon, Eugene, OR (1972-73).

Publications

1. Rich DJ, Gesellchen PD, Tong AW, Cheung W and Buckner CK: Alkylating derivatives of amino acids and peptides: Effects on vasopressin-stimulated water loss from isolated toad bladder. **J Med Chem** 18: 1004-1010, 1975.

2. Burger DR, Finke P, Vandenbark AA, Tong A, Vetto RM, Campbell JR. Sensitisation to neuroblastoma. **Lancet**. 2(7980):310, 1976.

3. Tong A, Burger DR, Finke P, Barney C, Vandenbark AA and Vetto RM: Leukocyte Adherence Inhibition-Assessment of mechanism and relationship to patient evaluation. **Cancer Res** 39: 597-603, 1979.

4. Vandenbark AA, Hallum HV, Swank RL, Tong AW and Burger DR: Myelin basic protein binding cells in active multiple sclerosis. **Ann Neurol** 6: 8-12, 1979.

5. Tong AW: Cytofluorometric evaluation of antigen specific rosette forming cells in humans. **Doctorate Thesis**, Department of Microbiology & Immunology, University of Oregon Health Sciences Center, 1980.

6. Tong AW, Vandenbark AA, Kraybill WG, Vetto RM, Burger DR: Flow cytofluorometric detection of tumor specific rosette forming cells in patients with squamous cell carcinoma of the head and neck**. Cancer Res** 42: 2949-2955, 1982.

7. Tong AW, Vandenbark AA, Kraybill W, Burger DR, Hefeneider S, Golding B: Flow cytofluorometric detection of antigen specific rosette forming cells in humans. **J Immunol Methods** 56: 63-74, 1983.

8. Tong AW, Lee JC, Stone MJ: Characterization of two human small cell lung carcinoma reactive monoclonal antibodies generated by a novel immunization approach. **Cancer Res** 44: 4987-4992, 1984.

9. Tong AW, Lee JC, Stone MJ: Discrimination of human small cell and non-small cell lung tumors by a panel of monoclonal antibodies. **J Natl Cancer Inst** 77: 1023-1033, 1986.

10. Tong AW, Lee JC, Stone MJ: Characterization of a monoclonal antibody having selective reactivity with normal and neoplastic plasma cells. **Blood** 69: 238-245, 1987.

11. Yoshihara PH, Thieme T, Finke P, Barney C, Tong A, Burger DR: Characterization of a T cell determinant defined by a monoclonal antibody (TH5.2) which is involved in the interleukin-2 producing and proliferative capabilities of T cells. **Cell Immunol** 108: 10-27, 1987.

12. Tong AW, Lee JC, Fay JW, Stone MJ: Elimination of clonogenic stem cells from human multiple myeloma cell lines by a plasma cell-reactive monoclonal antibody and complement. **Blood** 70.5: 1482-1489, 1987.

13. Tong AW, Stone MJ: Monoclonal antibodies: a new horizon for cancer treatment. **Baylor Proc** 1.3: 23-27, 1988.

14. Stone MJ, Tong AW, Fay JW, Lee JC: Selective depletion of human myeloma clonogenic stem cells from bone marrow cell preparations by a plasma cell reactive antibody and complement. **Cancer Detect Prevent** 12.3: 621-635, 1988.

15. Tong AW, Lee JC, Stone MJ: Expression of plasma cell-associated non-light chain antigens in patients with plasma cell dyscrasia and amyloidosis. In ***Amyloid and Amyloidosis***. T Isobe, A Shukuro, F Uchino, S Kito and E Tsubura (ed)., Plenum, New York, 1988, Pp 185-190.

16. Tong AW, Lee J, Wang RM, Dalton WS, Tsuruo T, Fay JW, Stone MJ: Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody MM4 and the P-glycoprotein-reactive monoclonal antibody. **Cancer Res** 49: 4829-4834, 1989.

17. Tong AW, Lee JC, Wang RM, Stone MJ: Augmentation of lymphokine activated killer cell cytotoxicity by monoclonal antibody against human small cell lung carcinoma. **Cancer Res** 49: 4103-4108, 1989.

18. Tong AW, Dalton WS, Tsuruo T, Fay JW, Stone MJ: Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement. In ***Bone Marrow Purging and Processing*** (Prog Clin Biol Res; Vol 333). S Gross, AP Gee, DA Worthington-White (eds), Wiley-Liss, New York, 1990, 155-164.

19. Lin TI, Tong AW, Dowben RM: Fluorescent probes for cancer detection. **J Clin Laser Med & Surgery** 8:39-41, 1990.

20. Tong AW, Nicodemus D, Burfoot A, Stone MJ: Quantification of non-light chain amyloid precursors and acute phase-proteins in AL-amyloid sera. In ***Amyloidosis***. JB Natvig, O Forre, G Husby, A Husebekk, B Skogen, K Sletten, P Westermark (eds), Kluwer, Dordrecht, 1991, Pp 207-210.

21. Huang YW, Richardson JA, Tong AW, Zhang BQ, Stone MJ, Vitetta ES: Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. **Cancer Res** 53:1392-1396, 1993.

22. Tong AW, Huang YW, Zhang BQ, Netto G, Vitetta ES, Stone MJ: Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice. **Anti-Cancer Res** 13: 593-598, 1993.

23. Tong AW: Purification of monoclonal antibodies***. American Society for Histocompatibility and Immunogenetics (ASHI) Laboratory Manual***, 3rd Edition (DL Phelan, EM Mickelson, HS Noreen, TW Shroyer, DM Clugg, A Nikaein eds.) Pp III.A.3.1-III.A.3.5, 1994.

24. Tong AW, Zhang BQ, Mues G, Hanson T, Solano M, Stone MJ: Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. **Blood** 84: 3026-3033, 1994.

25. Ameglio F, Alvino S, Trento E, Marcucci M, Pimpinelli F, Tong AW, Gandolfo GM, Greco C: Serum interleukin-10 levels in patients affected with multiple myeloma: correlation with the monoclonal component and disease progression. **Int J Cancer** 6: 1189-1192, 1995.

26. Tong AW, Stone MJ: CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity. **Leukemia and Lymphoma** 21: 1-8, 1996.

27. Tong AW, Su D, Mues G, Tillery G.W., Goldstein R, Klintmalm G, Stone MJ: Chemosensitization of human hepatocellular carcinoma cells with cyclosporin A in post-liver transplant patient plasma**. Clin Cancer Res** 2: 531-539, 1996.

28. Nemunaitis J, Klemow S, Tong A, Courtney A, Johnston W, Mack M, Taylor W, Solano M, Stone M, Mues G: Prognostic value of K-ras mutations, ras oncoprotein and c-erbB-2 oncoprotein expression in adenocarcinoma of the lung. **Am J Clin Oncol** 21 (2): 155-160, 1998.

29. Tong AW, Zhang YA, Nemunaitis J, Mues G: K-ras ribozyme for lung cancer. ***In "Methods in Molecular Medicine***", Scanlon KJ (ed), Chapter 11: 209-222, Humana Press , 1998.

30. Tong AW, Zhang YA, Bouffard DY, Nemunaitis, J: The use of ribozymes for gene therapy of lung

cancer. In "***Ribozymes in Gene Therapy of Cancer***", Scanlon KJ, Kashani-Sabet M (eds), Chapter 12; Pp. 151-164; Landes Bioscience, 1998.

31.Singh A, Tong A, Ognoskie N, Meyer W, Nemunaitis J: Improved survival in patients with advanced colorectal carcinoma failing 5-FU who received iroinotecan hydrochloride (CPT-11) and have high intratumor c-Fos expression. **Am J Clin Oncol** 21(5):499-469, 1998

32. Greco C, Ameglio F, Alvino F, Mosiello A, Cianciulli AM, Venturo I, Del Monte G, Giampaolo M, Tong AW, Gandolfo GM: Phenotypic and genotypic alterations characterize patients bearing plasma cell dyscrasias with high M-component. **Cell Prolif** 32: 231-238, 1999.

33. Zhang YA, Nemunaitis J, Tong AW: Anti-K-ras ribozyme adenoviral vector for gene therapy of non-small cell lung cancer. *In* ***"Gene Therapy of Cancer: Methods and Protocols***", W. Walther, U. Stein (eds), Chapter 15: Pp. 261-271, Humana Press, 2000.

34. Nemunaitis J, Cox J, Hays S, Meyer W, Ognoskie N, Courtney A, Young Y, Tong A: Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat. **Cancer Invest**. 18:185-90, 2000.

35. Zhang YA, Nemunaitis J, Tong AW. The generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells. In "***Molecular Biotechnology***", Walker JM (ed), 15: 39-49; Humana Press, 2000.

36. Tong AW, Seamour B, Chen J, Su, D, Ordonez G, Frase L, Netto, G, Stone MJ: CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. **Leukemia Lymphoma** 26: 543-558, 2000.

37. Tong AW, Seamour B, Vukelja S, Hyman W, Richards D, Stein L, Maples PB, Nemunaitis J: Cellular immune profile of advanced cancer patients. **Am J Clin Oncol** 23: 463-72, 2000.

38. Zhang YA, Nemunaitis J, Scanlon KJ, Tong AW: Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. **Gene Therapy** 7(23): 2041-2050, 2000.

39. Tong AW, Zhang YA, Cunningham C, Maples P, Nemunaitis J. Potential clinical application of anti-oncogene ribozymes for human lung cancer. Clin Lung Cancer 2: 220-226, 2001.

40. Tong AW, Papayoti M, Netto G, Ordonez G, Stone MJ. The growth inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Research 7: 691-703, 2001.

41. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Radlev B, Olson S, Kim D. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility, and biological activity. Gene Therapy 8: 746-759, 2001.

42. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer (Review). Cancer Gene Therapy 10: 1-13, 2003.

43. Stone MJ, McElroy YG, Pestronk A, Reynolds JL, Newman JT, Tong AW. Human monoclonal macroglobulins with antibody activity. Semin Oncol 30: 318-324, 2003.

44. Nemunaitis J, Cunningham C, Tong AW, Scott AS, Rich D, Blackburn A, Sands B, Freeman S. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Therapy 10:341-52, 2003.

45. Cunningham CC, Chada S, Merritt J, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, van Wart Hood J, Coffee K, Nemunaitis J. Clinical and Local Biological Effects of an Intratumoral Injection of mda-7 (INGN 241) in Patients with Advanced Carcinoma; a Phase I Study. Molecular Therapy 11:149-59, 2005.

46. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto, G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh P, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J, Chada S. Intratumoral injection of INGN 241, a non-replicating adenovector expressing the melanoma-differentiation associated antigen-7 (MDA-7/IL-24): Biologic outcome in advanced cancer patients. Molecular Therapy 11:160-72, 2005.

47. Konduri K, Sahota SS, Babbage G, Tong AW, Kumar P, Newman JT, Stone, MJ. Immunoglobulin M myeloma: Evaluation of molecular features and cytokine expression. Clin Lymphoma 5: 285-289, 2005.

48. Tong AW, Zhang YA, Nemunaitis J. Small interfering RNA for experimental therapy (review). Curr Opin Mol Therap 7:114-24, 2005.

49. Tong AW. Micro-RNA and Non-small cell lung cancer (review). Current Molecular Medicine 6: 339-349, 2006.

50. Tong, AW. Oncolytic Viral Therapy for Human Cancer: Challenges Revisited (review). Drug Development Research 66: 260-277, 2006.

51. Zhang YA, Nemunaitis J, Samuel S, Chen P, Shen Y, Tong AW. Anti-tumor activity of an oncolytic adenovirus-delivered oncogene siRNA. Cancer Res (accepted for publication), 2006.

52. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples P, Chamberlin T, Shawler D, Fakrai H. Phase II study of Lucanix, a transforming growth factor β2 (TGF-β2) antisense gene modified allogeneic tumor cell vaccine in advanced stage non small cell lung cancer (NSCLC). (submitted).

Abstracts (Presentations in national and international conferences)

1. Tong A, Burger DR and Vandenbark AA: Enumeration of antigen binding cells in human peripheral blood by rosette formation with antigen conjugated erythrocytes. ASM Abstracts 1977: 108, 1977.
2. Tong A, Finke P, Burger DR and Vandenbark AA: Influence of serum factors in the mechanism of Leukocyte Adherence Inhibition (LAI) test. Fed Proc 37.6: 1282, 1978.
3. Burger DR, Tong A, Finke P, Vandenbark A and Vetto RM: Leukocyte Adherence Inhibition: Mechanism. Proc Int Workshop on LAI 1: 7, 1978.
4. Burger DR, Tong A, Finke P, Vandenbark A and Vetto RM: Leukocyte Adherence Inhibition: Correlation with dermal tests, reactivity in patient contacts, and monitoring of human cancer. Proc Int Workshop on LAI 1: 14, 1978.
5. Tong AW, Kraybill W, Burger DR, Vandenbark AA: Laser cytofluorometric enumeration of tumor specific antigen binding cells in patients with squamous cell carcinoma of the head and neck. Fed Proc 39.3: 3520, 1979.
6. Vandenbark AA, Burger DR, Hallum HV, Tong, A: Implication of basic protein binding cells in active multiple sclerosis. Fed Proc 38.3: 897, 1979.
7. Tong AW, Vandenbark AA, Burger DR and Hefeneider S: Cytofluorometric determination of cytophilic antibody mediated antigen specific rosette formation. Fed Proc 39.3: 464, 1980.
8. Hefeneider SH, Vandenbark AA and Tong AW: Cellular recognition of conventional and tumor antigens. Fed Proc 40.3: 1040, 1981.
9. Yoshihara P, Jones R, Tong A, Burger D: A functional subset of human T helper cells defined

by a monoclonal antibody reactive to 20% of T-helper cells. Fed Proc 42.3: 718, 1983.

10. Tong AW, Lee JC, Stone MJ: Generation of monoclonal antibodies reactive to small cell lung carcinoma-associated antigens using a novel immunization approach. Hybridoma 3.1: 82, 1984.
11. Tong AW, Lee JC, Stone MJ: Diagnosis of human lung carcinoma cell types using a panel of monoclonal antibodies. AACR Proceedings 25: 249. 1984.
12. Tong AW, Lee JC, Stone MJ: Characterization of two human multiple myeloma-reactive monoclonal antibodies generated by an alternate immunization approach. AACR Proceedings 26: 288, 1985.
13. Tong AW, Lee JC, Greene CL, Stone MJ: Differentiation of human small cell and non-small cell lung tumors by a panel of monoclonal antibodies. In: Abstracts for the IV World Conference on Lung Cancer. Pp. 136. Toronto, 1985.
14. Tong AW, Lee JC, Stone MJ: Reactivity of two human multiple myeloma-reactive monoclonal antibodies generated by an alternate immunization approach. Exp Hematol 13: 389, 1985.
15. Tong AW, Lee JC, Fay JW, Stone MJ: Complement-dependent antibody-mediated cytolysis of myeloma cells in vitro: A model for autologous bone marrow purging. AACR Proceedings 27: 171, 1986.
16. Tong AW, Lee JC, Fay JW, Stone MJ: Monoclonal antibody-mediated toxicity of human myeloma cells in vitro: A model for autologous bone marrow purging. Abstract VIth Intl Congress Immunol, pp. 524. Toronto: 1986.
17. Tong AW, Fay JW, Stone MJ: Elimination of human myeloma clonogenic stem cells by monoclonal antibody and complement: A model for purging multiple myeloma bone marrow in vitro. Blood 68.5 (suppl I): 242a, 1987.
18. Tong AW, Lee JC, Stone MJ: Expression of plasma cell-associated non-light chain antigens in patients with amyloidosis. Abstract Vth Intl Symp Amyloidosis: 43, 1987.
19. Tong AW, Fay JW, Lee JC, Stone MJ: Immunomagnetic depletion of human myeloma clonogenic stem cells: A model for purging multiple myeloma bone marrow in vitro. Blood 70.5 (suppl I): 324a, 1987.
20. Tong AW, Lee JC, Wang RM, Fay JW, Dalton WS, Stone MJ: Depletion of chemoresistant human multiple myeloma clonogenic stem cells using the monoclonal antibody MM4 and complement. Blood 72 (suppl I): 258a, 1988.
21. Tong AW, Wang RM, Dalton WS, Tsuruo T, Stone MJ: Elimination of human multiple myeloma clonogenic stem cells using the P-glycoprotein-reactive monoclonal antibody MRK-16 and the plasma cell-reactive monoclonal antibody MM4. Blood 72 (suppl I): 258a, 1988.
22. Fay J, Miller G, Tong A, Stone M: Treatment of autologous marrow cells with etoposide (VP-16) and methylprednisolone prior to transplantation in patients with lymphoid malignancies. Blood 72 (suppl I): 386a, 1988.
23. Tong AW, Lee JC, Wang RM, Stone MJ: Combined cytotoxicity of lymphokine activated killer cells and monoclonal antibody against human small cell lung carcinoma. AACR Proceedings 30: 366, 1989.
24. Tong AW, Wang RM, Dalton WS, Tsuruo T, Stone MJ: Deletion of melphalan and multi- drug resistant human myeloma clonogenic cells by monoclonal antibody and complement. AACR Proceedings 30: 391, 1989
25. Tong AW, Fay JW, Dalton WS, Stone MJ: Depletion of doxorubicin and melphalan-resistant human myeloma stem cells by monoclonal antibody and complement. Exp Hemtol 17: 658, 1989.
26. Tong AW, Wang RM, Dalton WS, Fay JW, Stone MJ: Depletion of refractory clonogenic cells from primary bone marrow cultures by the plasma cell monoclonal antibody MM4 and complement. Blood 74 (Suppl I): 201a, 1989.
27. Tong AW, Wong C, Miller G, Fay JW, Stone MJ: Immunopharmacologic depletion of human clonogenic myeloma cells. AACR Proceedings 31: 287, 1990.
28. Stone M, Amlot P, Fay J, Till M, Ghetie V, Collins R, Tong A, May R, Newman J, Clark P, Thorpe P, Uhr J, Vitetta E: Immunotoxin therapy of B cell lymphoma. Blood 76 (suppl I): 495a, 1990.

29. Tong AW, Hefeneider S, Wong C, Stone MJ: Modulation of human multiple myeloma clonogenic colony formation by Interleukin-6. AACR Proceedings 32: 230, 1991.
30. Wang XJ, Simoni J, Perlman PO, Stone M, Tong A, Morrow KJ Jr: A myeloma specific protein characterized with a monoclonal antibody MM4. Blood 77 (suppl I): 130a, 1991.
31. Tong AW, Huang Y, Zhang B, Netto G, Vitetta E, Stone MJ: Immunologic characterization of human multiple myeloma heterotransplants in severe combined immunodeficiency (SCID) mice. Blood 77 (Suppl I): 115a, 1991.
32. Tong AW, Hanson T, Stone MJ: Interleukin 6-modulation of human multiple myeloma clonogenic colony formation in patient primary bone marrow cultures. AACR Proceedings 33: 299, 1992.
33. Huang YW, Richardson JA, Tong AW, Zhang B, Stone MJ, Uhr JW and Vitetta ES: The growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease (SCID). AACR Proceedings 33: 51, 1992.
34. Tong AW, Hanson T, Zhang B, Stone MJ: Stimulation of human multiple myeloma clonogenic colonies by a monoclonal antibody to the B lineage antigen CD40. Blood 80 (suppl I): 485, 1992.
35. Tong, AW, Zhang B, Stone MJ: Characterization of CD40 expression on human myeloma cells. AACR Proceedings 34:454, 1993.
36. Tong AW, Su D, Ono K, Stone MJ: Enhancement of doxorubicin cytotoxicity to multidrug-resistant myeloma cells by cyclosporin A and the P-glycoprotein monoclonal antibody MRK16. In: Abstracts IV Intl Workshop Multiple Myeloma, Pp. 148, Rochester, 1993.
37. Tong AW, Su D, Ono K, Stone MJ: Effect of treatment with cyclosporin A and the P-glycoprotein monoclonal antibody MRK-16 on doxorubicin cytotoxicity in chemoresistant myeloma cell lines. Blood 82 (Suppl 1): 260a, 1993.
38. Tong AW, Klintmalm G, Su D, Stone MJ: Enhancement of doxorubicin cytotoxicity by cyclosporin A in human multidrug-resistant hepatocellular carcinoma. AACR Proceedings 35: 356, 1994.
39. Tong AW, Su D, Stone MJ: CD40 expression in human multiple myeloma. AACR Proceedings 35: 31, 1994.
40. Huang YW, Tong AW, Stone MJ, Pineiro L, Vitetta ES: Effect of an anti-ICAM1-dgA immunotoxin on human myeloma cells and hematopoietic progenitors in the bone marrow. AACR Proceedings 35: 527, 1994.
41. Mues G, Tong AW, Mack MJ, O'Brien Jr JC, Taylor W, Lieberman ZH, Stone MJ, et al: Therapeutic aspects of oncogene determination. Baylor Proceedings 7: 26, 1994.
42. Tong AW, Huang YW, Ghetie V, Nemunaitis J. Pineiro L, Vitetta E, Stone MJ: Enhancement of anti-CD54 immunotoxin cytotoxicity to human multiple myeloma cells by cyclosporin drugs. Blood 84 (Suppl 1): 170a, 1994.
43. Tong AW, Su D, Mues G, Solano M, Stone MJ: Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood 84 (Suppl 1): 170a, 1994.
44. Tong AW, Su D, Mues G, Tillery GW, Nemunaitis J, Goldstein R, Klintmalm G, Stone MJ: Effect of long- and short-term exposure to cyclosporin drugs on doxorubicin toxicity to multidrug-resistant human hepatocellular carcinoma cells. AACR Proceedings 36: 345, 1995.
45. Greco C, Marucci M, Alvino S, Tong AW, Biondino G, Mattei F, Venturo I, Lopez M, Cianciulli M, De Franceschi L, Ameglio F, Gandolfo GM: MGUS at risk of malignant transformation: Phenotypic and genotypic features. ASCO Proceedings 14: 426, 1995.
46. Tong AW, Seamour BK, Ordonez G, Stone MJ: Growth inhibition of human multiple myeloma cells by the CD40 ligand gp39. Blood 86 (Suppl 1): 59a, 1995.
47. Nemunaitis J, Klemow S, Tong A, Johnston W, Courtney A, Taylor W, Mack M, Solano M, Mues G: Correlation of multiple oncogene alterations with survival in 103 patients with adenocarcinoma of the lung. Blood 86 (Suppl 1): 737a, 1995.
48. Tong AW, Su D, Mues G, Tillery GW, Goldstein R, Klintmalm G, Stone MJ: Enhancement of doxorubicin cytotoxicity to human hepatocellular carcinoma cells with post-liver transplant patient plasma containing cyclosporine A. AACR Proceedings 37:329, 1996.
49. Tong AW, Su D, Mues G, Tillery G, Goldstein R, Klintmalm G, Stone MJ: Cyclosporin A-modulation of multidrug resistant hepatocellular carcinoma (HCC) in liver transplant patients.

Transplantation 1996.

50. Zhang YA, Nemuanitis J, Mues G, Scanlon KJ, Tong AW: In vitro suppression of human non-small cell lung cancer (NSCLC) cell growth by an anti-K-ras ribozyme. FASEB J 10: A1409, 1996.
51. Seamour BK, Mues G, Tong AW: Decreased multiple myeloma (MM) cell growth following transfection with an interleukin-6 (IL-6) plasmid. FASEB J 10: A1350, 1996.
52 Tong AW, Seamour B, Su D, Ordonez G, Stone MJ: CD40-ligand expression and growth regulation of human multiple myeloma cells. Blood 88 (Suppl I): 99a, 1996.
53. Zhang YA, Mues G, Nemunaitis J, Scanlon KJ, Tong AW: Inhibition of human non-small cell lung cancer growth in vitro by a recombinant anti-K-ras adenoviral vector. AACR Proceedings 38:40, 1997.
54. Tong AW, Banchereau J, Chen J, Ordonez G, Stone MJ: Induction of apoptosis by CD40 ligand in human multiple myeloma cells. Blood 90 (Suppl I), 384, 1997.
55. Papayoti MH, Tong AW, Banchereau J, Stone MJ: Induction of human breast carcinoma cell apoptosis by CD40-ligand. AACR Proceedings 39:3961, 1998.
56. Zhang YA, Nemunaitis J, Scanlon KJ, Tong AW: In vitro growth inhibition of human non-small cell lung cancer cells by a recombinant anti-K-ras adenoviral vector. Am Soc Gene Therapy 1:317, 1998.
57. Tong AW, Zhang YA, Scanlon KJ, Nemunaitis J: Anti-tumorigenic effect of a recombinant anti-K-ras ribozyme adenoviral vector on human non-small cell lung cancer (NSCLC) xenografts. Cancer Gene Therapy 5: S32, 1998.
58. Tong AW, Chen J, Seymour B, Frase L, Netto G, and Stone MJ: Induction of Fas-independent apoptosis in human multiple myeloma cells by CD40 ligand**.** Blood 92 (Suppl I): 2634; 1998.
59. Zhang YA, Nemunaitis J, Ordonez GA, Scanlon KJ, Tong AW: Induction of apoptosis contributes to the anti-tumorigenic effect of a recombinant anti-K-ras adenoviral vector against human non-small cell lung cancer xenografts. Proc Am Soc Gene Therapy 2:700, 1999.
60. Tong AW, Zhang YA, Maples PB, Scanlon KJ, Nemunaitis J. Anti-K-ras ribozyme adenoviral vector inhibits growth of pre-existing human non-small cell lung cancer (NSCLC) xenografts. Cancer Gene Therapy 6:S7, 1999.
61. Zhang YA, Nemunaitis J, Scanlon K, Tong A. Treatment with a recombinant anti-K-ras ribozyme adenoviral vector induces apoptosis and collaterally downregulates Bcl-2 anti-apoptotic subfamily genes in human non-small cell lung cancer (NSCLC) cells. Am Soc Gene Therapy, 2001.
62. Chada S, Nemunaitis J, Tong A, Zhang Y, Su D, Mhashikar A, Zhou-Yang H, Parker K, Wilson D, Merritt J, Coffee K. A Phase I dose-escalation study of Ad-mda-7 (INGN 241) in patients with advanced carcinoma. Cancer Gene Therapy 9 (suppl 1), 2002.
63. Chada S, Tong A, Su D, Mhashikar A, Yang H, Parker K, Wilson D, Merritt J, Nemunaitis J, Coffee K. Ad-mda7 (INGN 241) activates the immune response in patients with advanced carcinoma. Cancer Gene Therapy 9 (suppl 1), 2002
64. Cunningham CC, Richards D, Tong A, Y Zhang, Su D, Chada S, Mhashilkar A, Zhou-Yang H, Parker K, Wilson D, Nemunaitis J, Merritt J, Coffee K. A phase I dose-escalation pharmacokinetic and pharmcodynamic study of INGN 241 (Ad-mda7) in patients with advanced solid tumors. Cancer Gene Therapy 10 (suppl 1): S2, 2003.
65. Nemunaitis J, Cunningham C, Tong A, Edelman G, Paulson S, Mitch D, Post L, Freeman S. Pilot trial of intravenous (IV) infusion of a replication selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 in treatment of refractory cancer patients. Cancer Gene Therapy 10 (suppl 1): S13, 2003.
66. Tong AW, Chada S, Nemunaitis J, Su D, Cunningham C, Mhashilkar A, Parker K, Wilson D, Merritt J, Coffee K. Cancer Gene Therapy 10 (supp 1): S37, 2003.
67. Zhang YA, Nemunaitis J, Cunningham C, Senzer N, Samuel S, Chen P, Tong AW. Growth Suppression of Human Non-small Cell Lung Cancer Cells by Small Interfering RNA (siRNA) with Mutant *K-ras* Knockdown Activity. Cancer Gene Therapy (in press), 2003.
78. Rodrigues MS, Gomes EM, Hernandez R, Chang J, Kansopon J, Newman J, Stone MJ, Tong AW. Growth inhibition of human multiple myeloma cells by a selectively-replicating, oncolytic adenovirus armed with the CD154 (CD40-ligand) transgene. Cancer Gene Therapy (in press),

2005.

79. Gomes EM, Rodrigues MS, Hernandez R, Zhang YA, Kansopon P, Newman J, Stone MJ, Tong AW. Conditional-replicative adenovirus armed with CD154 (CD40L) displayed enhanced anti-tumor growth inhibitory properties against human breast cancer cells. Cancer Gene Therapy (in press), 2005.
80. Nemunaitis J, Dillman RO, Batra RK, Dubinett S, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Papper B, Hamilton C, DeVol E, Chamberlain T, Shawler D, Fakrai H. Phase II study of Lucanix, a TGF-β2 antisense gene modified allogeneic tumor cell vaccine in advanced stage nonsmall cell lung cancer (NSCLC). Cancer Gene Therapy (in press), 2005.
81. Shen Y, Tong A, Rao D, Cunningham C, Senzer N, Nemunaitis J. Role of cDNA microarray and proteomics in the development of molecular precision approaches for cancer therapy. Cancer Gene Therapy (in press), 2005.
82. Zhang YA, Samuel S, Chen P, Shen Y, Nemunaitis, J, Tong AW. Arming with a K-ras oncogene-reactive siRNA enhanced antitumor efficacy of ONYX-411, a selective replicative oncolytic adenovirus. Cancer Gene Therapy (in press), 2005.
83. Gomes EM, Rodrigues MS, Alcoceba Hernandez R, Kansopon J, Newman J, Stone MJ, Tong A. Enhanced anti-tumor growth inhibition by a conditional-replicative adenovirus armed with the CD154 (CD40L) transgene in human breast cancer cells. AACR Proceedings 47: 2166, 2005.
84. Nemunaitis J, Senzer N, Shen J, Maples P, Rao D, Tong A, Kumar P, Kuhn J, Zhang YA, Liao J, Khalil I, Hill C, Gazdar A. Clinical Study of Personalized Therapeutics Based on Genomic/Proteomic Profiling. Mol Therapeutics 13 (supplement 1): S21-S22, 2006.
85. Tong AW, Zhang YA, Samuel S, Chen P, Shen Y, Nemunaitis J. Target-Specific Knockdown and Enhanced Anti-Tumor Outcome by an Oncolytic Virus-Delivered Small Interfering RNA (siRNA) Mol Therapeutics 13 (supplement 1): S118-S119, 2006.
86. Edelman G, Senzer N, Nemunaitis M, Cunningham C, Sovern P, Tong A, Nemunaitis J. Phase I Trial of Intravenous Infusion of Onyx 015 and Enbrel in Solid Tumor Patients. Mol Therapeutics 13 (supplement 1): S144, 2006.
87. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples P, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II Study of Lucanix™ a Transforming Growth Factor β2 (TGF-β2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC). Mol Therapeutics 13 (supplement 1): S424-S425, 2006.

ACADEMIC COURSES TAUGHT

Course Director, Current Topics in Immunology (BMS 5302)
Baylor University, Waco (1992, 1994, 1996, 1998, 2000, 2002)

Course Director for Immunobiology (BIO4345)
University of Texas at Dallas (1992, 1995, 1996, 1997)

July 31, 2006